Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from CSL ( (AU:CSL) ).
CSL Limited announced its upcoming Capital Markets Day event to be held in Chicago, Illinois, USA, which will include a briefing for investors and analysts. The event, aimed at providing insights into the company’s strategic direction and financial performance, will be webcast live on the company’s website, highlighting CSL’s commitment to transparency and stakeholder engagement.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$248.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biotechnology industry, primarily focusing on developing and delivering innovative biotherapies and influenza vaccines. The company is known for its contributions to the healthcare sector, particularly in plasma-derived therapies and vaccines, with a strong market presence globally.
Average Trading Volume: 1,337,796
Technical Sentiment Signal: Sell
Current Market Cap: A$85.09B
Find detailed analytics on CSL stock on TipRanks’ Stock Analysis page.